Ying-Hao Shen

机构：Fudan University, Zhongshan Hospital · ORCID：0000-0002-3014-9338

发表论文 36 篇 · 总被引 96 次 · h-index 4

代表论文

• FMO2 + cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma (2025 · Journal for ImmunoTherapy of Cancer · 被引 23)
• FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, prospective phase Ⅱ trial. (2025 · Journal of Clinical Oncology · 被引 1)
• Data from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy (2024 · 被引 1)
• Supplementary Figure S7 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy (2024)
• Supplementary Figure S5 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy (2024)
• Supplementary Figure S11 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy (2024)